S. Guérif

3.4k total citations · 1 hit paper
65 papers, 1.5k citations indexed

About

S. Guérif is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Oncology. According to data from OpenAlex, S. Guérif has authored 65 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pulmonary and Respiratory Medicine, 17 papers in Radiation and 14 papers in Oncology. Recurrent topics in S. Guérif's work include Prostate Cancer Diagnosis and Treatment (41 papers), Prostate Cancer Treatment and Research (39 papers) and Advanced Radiotherapy Techniques (17 papers). S. Guérif is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (41 papers), Prostate Cancer Treatment and Research (39 papers) and Advanced Radiotherapy Techniques (17 papers). S. Guérif collaborates with scholars based in France, United States and Italy. S. Guérif's co-authors include P. Pommier, Sven D’haese, George van Andel, Howard Kynaston, Sophie D. Fosså, Corneel Coens, Andrew Bottomley, Paolo Gontero, Fabio Efficace and A. Akdaş and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

S. Guérif

59 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial

2010 335 citations V. Beckendorf, S. Guérif et al. International Journal of Radiation Oncology*Biology*Physics profile →

Peers

Countries citing papers authored by S. Guérif

Since Specialization

Citations

This map shows the geographic impact of S. Guérif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Guérif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Guérif more than expected).

Fields of papers citing papers by S. Guérif

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Guérif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Guérif. The network helps show where S. Guérif may publish in the future.

Co-authorship network of co-authors of S. Guérif

This figure shows the co-authorship network connecting the top 25 collaborators of S. Guérif. A scholar is included among the top collaborators of S. Guérif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Guérif. S. Guérif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial 2024 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), (unknown), S. Guérif, R. de Crevoisier, G. Calais, (unknown), Gauthier Bouche, Christophe Hennequin, J Crétin, Yazid Belkacémi, (unknown), (unknown), (unknown), (unknown), (unknown), Antoine Simon, Caroline Léger, V. Beckendorf, Bernard Dubray, (unknown)	1
2	Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile 2024 ·Blood Advances ·Zhihong Zeng, (unknown), (unknown), (unknown), S. Guérif, Veronique De Brabandere, Céline Amara, Eline Dejonckheere, Angéla Virone-Oddos, Marielle Chiron, Marina Konopleva, Mélissa Dullaers	17
3	Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML 2023 ·Blood ·Zhihong Zeng, (unknown), (unknown), (unknown), S. Guérif, Veronique De Brabandere, (unknown), (unknown), Angéla Virone-Oddos, Marielle Chiron, Mélissa Dullaers, Marina Konopleva	1
4	OC-0433 GETUG-AFU 22 phase II randomized trial : final results on clinical outcomes with immediate SRT 2023 ·Radiotherapy and Oncology ·(unknown), S. Guérif, Florence Castan, E. Meyer, S. Supiot, É. Lagneau, (unknown), Philippe Ronchin, (unknown), (unknown), H. Hamidou, Ali Hasbini, G. Créhange, P. Pommier, (unknown), (unknown), (unknown), (unknown), Laurent Salomon, Paul Sargos	1
5	Comparison between MRI and choline-PET trans-perineal target biopsies and saturation biopsies for detection and topography of intra-prostatic recurrence after primary radiation therapy for prostate cancer 2021 ·Progrès en Urologie ·(unknown), M. Vallée, Pierre Ingrand, (unknown), (unknown), (unknown), S. Guérif	1
6	An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities 2020 ·Molecular Cancer Therapeutics ·Céline Nicolazzi, Anne Caron, Alexia Tellier, (unknown), Jan Pinkas, Gillian Payne, (unknown), S. Guérif, (unknown), Raffaele Baffa, Matteo Fassan, Julien Adam, (unknown), Véronique Blanc	23
7	Delineation of the Prostate Bed: The “Invisible Target” Is Still an Issue? 2017 ·Frontiers in Oncology ·I. Latorzeff, Paul Sargos, (unknown), S. Supiot, S. Guérif, C. Carrié	13
8	DNA-PKcs Expression Is a Predictor of Biochemical Recurrence After Permanent Iodine 125 Interstitial Brachytherapy for Prostate Cancer 2016 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), S. Guérif, (unknown), (unknown), Jacques Irani, Gaëlle Fromont	10
9	Curiethérapie des cancers de la prostate 2016 ·Cancer/Radiothérapie ·P. Pommier, S. Guérif, D. Peiffert, G. Créhange, Jean‐Michel Hannoun‐Lévi, R. de Crevoisier	5
10	Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient–nurse satisfaction 2013 ·Supportive Care in Cancer ·Thierry Lebrét, (unknown), Alain Lortholary, Claude El Kouri, Laurent Bastit, (unknown), (unknown), X. Murraciole, S. Guérif	3
11	Curiethérapie prostatique de haut débit de dose 2013 ·Cancer/Radiothérapie ·P. Nickers, Pierre Blanchard, Jean‐Michel Hannoun‐Lévi, Alberto Bossi, O. Chapet, S. Guérif	7
12	Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer 2012 ·Strahlentherapie und Onkologie ·(unknown), (unknown), (unknown), (unknown), Marie‐Aimée Perrouin‐Verbe, (unknown), S. Guérif, Georges Fournier, Olivier Pradier, Antoine Valéri	12
13	DNA-PKcs Expression Predicts Response to Radiotherapy in Prostate Cancer 2012 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), S. Guérif, (unknown), Jacques Irani, Gaëlle Fromont	67
14	70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial breakdown → 2010 ·International Journal of Radiation OncologyBiologyPhysics ·V. Beckendorf, S. Guérif, É. Le Prisé, Jean‐Marc Cosset, A. Bougnoux, B. Chauvet, Naji Salem, O. Chapet, (unknown), Jean‐Marc Bachaud, P. Maingon, Jean‐Michel Hannoun‐Lévi, L Malissard, Antoine Simon, P. Pommier, (unknown), Bernard Dubray, Jean‐Léon Lagrange, Élisabeth Luporsi, Pierre Bey	335
15	An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer 2008 ·European Journal of Cancer ·George van Andel, Andrew Bottomley, Sophie D. Fosså, Fabio Efficace, Corneel Coens, S. Guérif, Howard Kynaston, Paolo Gontero, George N. Thalmann, A. Akdaş, Sven D’haese, Neil K. Aaronson	368
16	Analyse clinique et dosimétrique de 469 patients traités en France en 2005 par implantation prostatique de grains d'iode 125 IsoSeed Bebig : rapport pour le Comité économique des produits de santé (CEPS) 2007 ·Cancer/Radiothérapie ·J M Cosset, (unknown), D. Peiffert, S. Guérif, A. Labib, (unknown), Peter Martin, Philippe Quétin, (unknown), T Flam, Nicolas Thiounn, (unknown), (unknown), M. Housset, D. Pontvert, Bernard Asselain, L. Chauveinc	7
17	Brachytherapy versus prostatectomy in localized prostate cancer: Results of a French multicenter prospective medico-economic study 2007 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Béatrice Le Vu, Jean‐Marc Cosset, P. Pommier, D. Peiffert, M. Delannes, T Flam, S. Guérif, Naji Salem, L. Chauveinc, Alain Livartowski	76
18	[Multisite validation study of questionnaire assessing out-patient satisfaction with care questionnaire in ambulatory chemotherapy or radiotherapy treatment]. 2006 ·PubMed ·Rollon Poinsot, (unknown), T. Conroy, Alexia Savignoni, Bernard Asselain, I. Léonard, (unknown), (unknown), (unknown), (unknown), C Rodary, Mariette Mercier, (unknown), (unknown), Pascal Antoine, S. Guérif, S Schraub, Sylvie Dolbeault, Anne Brédart	39
19	Délimitation des volumes-cibles et des organes critiques pour la radiothérapie conformationnelle du cancer de la prostate : expérience des essais français d’escalade de dose 2002 ·Cancer/Radiothérapie ·V. Beckendorf, J.M. Bachaud, Pierre Bey, S. Bourdin, C. Carrié, O. Chapet, D. Cowen, S. Guérif, (unknown), (unknown), P. Maingon, É. Le Prisé, P. Pommier, Jean-Marc Simon	9
20	Curved angiocatheter metal guide for the implantation in velo-tonsillar carcinomas 2000 ·Radiotherapy and Oncology ·M. Lapeyre, (unknown), S. Hoffstetter, S. Guérif, Pierre Bey	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact